News | June 05, 2021
Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The GMP certificate is valid for three years until April 2024.
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
